AI Article Synopsis
- Functional dyspepsia (FD) is treated with serotonin receptor agonists, but their effectiveness varies across studies, prompting a meta-analysis to evaluate their efficacy and safety in treating FD.
- The meta-analysis included 10 randomized controlled trials (RCTs) with nearly 900 patients taking serotonin receptor agonists and 640 on placebo, examining response rates and symptom scores.
- Results show that patients on serotonin receptor agonists had better response rates and improved symptom scores compared to those on placebo, indicating these medications are more effective for treating FD.
Article Abstract
Introduction: Functional dyspepsia (FD) is typically treated with serotonin receptor (5-HT) agonists such as cisapride, mosapride, tegaserod and tandospirone citrate. However, there are conflicting efficacy data, possibly due to significant heterogeneity between studies. In this meta-analysis, we analyzed the efficacy and safety data from studies evaluating the efficacy of serotonin receptor agonists in patients with FD.
Material And Methods: Relevant studies were selected from the Medline, Cochrane, EMBASE, and Google Scholar databases. The meta-analysis included 10 RCTs which evaluated the efficacy of serotonin receptor agonists in patients with FD (final total of 892 patients in the serotonin receptor agonist group, and 640 participants in the placebo group). The primary outcomes were the response rates and abdominal symptoms score. The Cochrane Collaboration's tool was used to assess risk. Sensitivity analysis was carried out using the leave-one-out approach.
Results: Patients treated with serotonin receptor agonists had a significantly higher response rate compared to placebo-treated patients (pooled OR = 2.99; 95% CI: 1.15-7.77; = 0.025). Patients treated with serotonin receptor agonists had a significant improvement in symptom scores compared to the placebo group (pooled standardized mean difference = -0.43; 95% CI: -0.83 to -0.04; = 0.031). Sensitivity analysis indicated that the pooled estimates for abdominal symptom score might be affected by the Yeoh (1997) study.
Conclusions: Serotonin receptor agonists had a significantly higher efficacy compared to placebo in the treatment of FD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348349 | PMC |
| http://dx.doi.org/10.5114/aoms.2017.69234 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparing the efficacy of serotonin and EGTA on postpartum hypocalcemia.
J Dairy Sci
January 2025
Department of Animal and Dairy Sciences, University of Wisconsin-Madison, Madison, WI, 53701. Electronic address:
Inducing a transient state of hypocalcemia prepartum mobilizes stored calcium (Ca) before the abrupt demand for Ca at parturition thus more tightly regulating postpartum hypocalcemia. Prepartum transient hypocalcemia can be achieved through intravenous infusions of either the precursor to serotonin, 5-hydroxy-tryptophan (5HTP) or a Ca chelating agent, ethylene-glycol-tetraacetic acid (EGTA). This study aimed to compare the ability of 5HTP and EGTA treatments to prevent postpartum hypocalcemia.
View Article and Find Full Text PDFPopulation pharmacokinetics of blonanserin in Japanese adolescent and adult patients with schizophrenia.
Drug Metab Pharmacokinet
November 2024
Clinical Research, Drug Development Division, Sumitomo Pharma Co., Ltd., 33-94, Enoki-cho, Suita, Osaka, 564-0053, Japan. Electronic address:
The second-generation antipsychotic blonanserin is a highly selective, full antagonist of dopamine D and D and serotonin 5-HT receptors. It is currently prescribed for patients with schizophrenia in Japan. We aimed to develop a population pharmacokinetic model of oral blonanserin, including data from 12 to 77 years old patients, to assess the covariates that influence blonanserin pharmacokinetics and evaluate appropriate dosage regimens in adolescents versus adults.
View Article and Find Full Text PDFBackground: Psychotic symptoms may manifest in Alzheimer’s disease (AD), especially in advanced disease stages and in patients with higher polygenic risk scores for schizophrenia (SCZ‐PRS). Such genetic risk seems also to influence grey matter volume (GMV) alterations in patients with psychosis. Since multiple neurotransmitter systems, namely dopamine (DA) and serotonin (5‐HT), have been implicated in psychosis, the aim of this study was to investigate whether a SCZ‐PRS may explain variance in the association between GMV and the cerebral distribution of DA and 5‐HT.
View Article and Find Full Text PDFThe impact of polygenic risks on neurotransmitter‐related grey matter atrophy in Alzheimer’s disease.
Alzheimers Dement
December 2024
University of Parma, Parma, Italy
Background: Tau protein tangles have been recently shown to accumulate in multiple brainstem nuclei in pre‐cortical Alzheimer’s disease (AD) stages. The impact of neurotransmission alterations on brain atrophy and their genetic correlates in AD remain unexplored. Therefore, the aims of this study were: 1) to investigate associations between grey matter (GM) loss across the AD continuum and the distribution of multiple neurotransmitter receptors/transporters; 2) to investigate the impact of polygenic risk scores for AD (PRSs) on such associations.
View Article and Find Full Text PDFNeural circuits expressing the serotonin 2C receptor regulate memory in mice and humans.
Alzheimers Dement
December 2024
Baylor College of Medicine, Houston, TX, USA
Background: A decline in memory is a hallmark of Alzheimer’s disease (AD). Experiments in rodents and post‐mortem studies in humans with AD suggest that serotonin (5‐HT) plays a role in memory, but the molecular and neural mechanisms mediating its effects are unknown.
Method: 100,000 individuals in UK Biobank were studied for the role of serotonin 2C receptor (5‐HTR) in the regulation of memory.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!